论文部分内容阅读
疱疹性脑炎是由疱疹病毒引起的一种死亡率很高的疾病,以往治疗很少成功。1973年,Merigan发现,在免疫抑制病人,阿糖胞嘧啶及其它核苷酸类对弥散性带状疱疹无效。1975年,由十五个单位参加的合作研究组证实,疱疹净(Idoxuridine)治疗全身疱疹感染有效,但毒性太大,不能接受。以后,该组试用阿拉伯腺嘌呤(ara-A)先后治愈了疱疹性角膜炎和局部或弥散性带状疱疹。接着,他们又用该药在疱疹性脑炎的治疗上获得成功。方法:15毫克/公斤/天,静滴,共十天。结果:ara-A大大降低了疱疹性脑炎病人的病死率。在脑活检组织培养证实有疱疹病毒的病例中,对照组死亡率为70％,治疗组下降至28％。测定白细
Herpes simplex encephalitis is a highly fatal disease caused by the herpes virus that has been less successful in the past. In 1973, Merigan found that in patients with immunosuppression, cytarabine and other nucleotides are not effective against diffuse herpes zoster. In 1975, a collaborative study of 15 units confirmed that Idoxuridine was effective in treating herpes zoster but was too toxic to accept. Later, the group trial of ara-A (ara-A) has cured herpes keratitis and local or diffuse shingles. Then they used the drug again for the treatment of herpes encephalitis. Method: 15 mg / kg / day, intravenous infusion, a total of ten days. Results: ara-A greatly reduced the mortality of herpes encephalitis patients. In cases of herpesvirus confirmed by brain biopsies, the mortality rate was 70% in the control group and 28% in the treatment group. Determination of white